PRESS RELEASE

Q2 2020 — Press release

Q2 2020PDF · 14 pages253 KB
Page 1 of 7
N E W S R E L E A S E
(For Immediate Release)
UNITEDHEALTH GROUP CONTINUES EFFORTS TO COMBAT COVID-19
REPORTS SECOND QUARTER PERFORMANCE
MINNETONKA, Minn. (July 15, 2020) – During the second quarter of 2020, UnitedHealth Group (NYSE: UNH) expanded its
COVID-19 response efforts, proactively supporting patients, customers, care providers and communities, including investing in
outreach programs and clinical innovations to address the urgent needs of underserved communities disproportionately impacted
by the disease.
“Our 325,000 dedicated team members, including the 120,000 clinicians serving on the front lines of care, have tirelessly
responded to COVID-19 with agility, innovation and compassion,” said David S. Wichmann, chief executive officer of
UnitedHealth Group. “We moved swiftly to assist the people we serve and their care providers, including the provision of $3.5
billion in proactive voluntary customer assistance and accelerated care provider funding. We remain committed to taking further
actions to address any future imbalances as a result of the pandemic.”
Second quarter 2020 net earnings and adjusted net earnings per share of $6.91 and $7.12 were substantially higher than
anticipated due primarily to the unprecedented, temporary deferral of care in the Company’s risk-based businesses. The Company
expects these results will be offset in the quarters ahead by the assistance measures already taken, the resumption of deferred care
and future COVID-19 cost and economic impacts. As the pandemic advanced, access to and demand for care was most
constrained from mid-March through April, began to recover in May and approached more typical levels by the end of the second
quarter. The Company is maintaining its full year earnings per share outlook for 2020 of net earnings of $15.45 to $15.75 per
share and adjusted net earnings of $16.25 to $16.55 per share.
Investments by the Company to support those affected by COVID-19 include extensive local market relief efforts, innovative
health workforce safety initiatives, treatment and testing innovations and support for seniors and individuals experiencing
homelessness and food insecurity. Building on years of investments in support of advancing health equity, the Company invested
another $100 million in affordable housing to address homelessness and led numerous additional efforts to increase the
availability of testing and treatment for COVID-19, including establishing more than 500 testing centers in underserved
communities, deploying free COVID-19 mobile and local testing sites, health and safety kits, and education and outreach
resources to underserved communities. The Company is also leading innovative clinical research to study the elevated risks and
treatment options for COVID-19 associated with health conditions that disproportionately impact minority populations. A
summary of the Company’s COVID-19 response to date is included as part of this release.

-- 1 of 14 --

Page 2 of 7
Quarterly Financial Performance
Three Months Ended
June 30,
2020
June 30,
2019
March 31,
2020
Revenues $62.1 billion $60.6 billion $64.4 billion
Earnings from Operations $9.2 billion $4.7 billion $5.0 billion
Net Margin 10.7% 5.4% 5.2%
 UnitedHealth Group’s second quarter 2020 revenues increased $1.5 billion to $62.1 billion, reflecting growth at Optum
and the UnitedHealthcare public-sector and senior businesses, partially offset by economic-related impacts at
UnitedHealthcare commercial and global.
 Second quarter earnings from operations increased $4.5 billion to $9.2 billion, impacted primarily by the previously
described deferred care in the risk-based businesses, with this care expected to be delivered in future periods.
 Cash flows from operations were $10.0 billion or 1.5 times net income in the second quarter and $12.9 billion or 1.3
times net income year to date.
 The second quarter medical care ratio was impacted by the temporary deferral of care due to the pandemic, declining to
70.2% from 83.1% last year. The Company expects the medical care ratio to rise in coming quarters as needed care is
accessed. Favorable reserve development was $1.4 billion in the second quarter, nearly all related to the current year, and
primarily due to higher than expected care deferrals in late March, further lowering the second quarter medical care ratio.
Days claims payable were 50.4 days compared to 48.6 in the second quarter 2019 and 50.5 in the first quarter 2020.
 The operating cost ratio of 16.1% in the second quarter of 2020 increased from 13.9% in the same period last year,
primarily due to the health insurance tax, COVID-19 response efforts and business mix.
 The Company returned $1.2 billion to shareholders in the second quarter via dividends, while the debt to total capital
ratio was 40.9% at quarter end. Return on equity of 33.7% for the first half of 2020 reflects continued strong core
operating performance and the temporary impact of care deferrals experienced during the second quarter 2020.

-- 2 of 14 --

Page 3 of 7
UnitedHealthcare provides global health care benefits, serving individuals and employers, and Medicare and Medicaid
beneficiaries. UnitedHealthcare is dedicated to improving the value health care consumers receive by reducing the total cost of
care, enhancing the quality of care received, improving health and wellness and simplifying the health care experience.
Quarterly Financial Performance
Three Months Ended
June 30,
2020
June 30,
2019
March 31,
2020
Revenues $49.1 billion $48.6 billion $51.1 billion
Earnings from Operations $7.0 billion $2.6 billion $2.9 billion
Operating Margin 14.3% 5.4% 5.7%
 UnitedHealthcare second quarter revenues of $49.1 billion compare to $48.6 billion in the year ago quarter, as growth in
serving public-sector and senior programs was partially offset by commercial enrollment declines. UnitedHealthcare
public-sector and senior program revenue, including Medicare and Medicaid, grew by 7% year-over-year in the quarter
and by nearly 600,000 additional people served year to date, while commercial revenue was impacted by economic-
driven member attrition.
 Operating earnings of $7.0 billion compare to last year’s $2.6 billion, with comparatively higher growth and operating
margins compared to prior periods driven by the temporary impact of deferred care, net of COVID-19 treatment costs
and the initial impact of a decelerating economy. The Company expects future quarters will reflect the restoration of care
patterns and the impact of its $1.5 billion in customer assistance actions against the backdrop of an uncertain economic
recovery.
 Further UnitedHealthcare growth highlights include: Medicaid business wins in Kentucky and Indiana; continued growth
in serving people in dual special needs plans; gains in serving individuals’ health benefits needs in the commercial
marketplace; and launch of GetCovered, a national, multicarrier service offering consumers information, guidance,
enrollment, support and affordable coverage across 200 independent individual health and local Medicaid plans
supported by the Company’s HealthMarkets benefits representatives.

-- 3 of 14 --

Page 4 of 7
Optum is a health services business serving the global health care marketplace, including payers, care providers, employers,
governments, life sciences companies and consumers. Using market-leading information, data analytics, technology and clinical
insights, Optum helps improve overall health system performance: optimizing care quality, reducing health care costs and
improving the consumer experience.
Quarterly Financial Performance
Three Months Ended
June 30,
2020
June 30,
2019
March 31,
2020
Revenues $32.7 billion $28.0 billion $32.8 billion
Earnings from Operations $2.2 billion $2.1 billion $2.1 billion
Operating Margin 6.8% 7.5% 6.4%
 Optum second quarter revenues and operating earnings of $32.7 billion and $2.2 billion respectively advanced from
$28.0 billion and $2.1 billion a year ago, led by earnings growth at OptumHealth.
 OptumHealth served approximately 97 million people in the second quarter, compared to 95 million a year ago, while
revenue per consumer served grew 25% year-over-year driven by continued growth in value-based care arrangements.
The OptumHealth care delivery practices were impacted early in the quarter due to the pandemic. By June, care patterns
had returned to near normal levels. Over the course of the quarter, the Company accelerated the growth of its employed
and affiliated physicians at OptumCare.
 The OptumInsight revenue backlog rose to $19.4 billion at quarter end, an increase of nearly $1 billion year-over-year,
driven by growth in technology and managed services across the business. Activity levels within OptumInsight’s
volume-based services were negatively affected by care deferrals.
 At OptumRx, diversified growth in areas such as home infusion services, community-based behavioral health
pharmacies, e-commerce and specialty pharmaceuticals partially offset the negative impact of reduced first fill
prescription volumes, driven by COVID-19 related care deferral. As care delivery activity has been recovering over the
course of the quarter, script volumes have begun to return to more normal levels.
 Further Optum growth highlights include: extending geographic presence and distinctive capabilities through strategic
acquisitions in infusion services (Diplomat Pharmacy), post-acute care (NaviHealth) and digital behavioral health
(AbleTo); launching the Boulder Community Health partnership; providing testing services in California, Indiana and
Florida; and launching digital at home and rare disease pharmacy programs.

-- 4 of 14 --

Page 5 of 7
COVID-19 Response to Date
Coronavirus (COVID-19) is profoundly impacting the health of people around the world, as well as our global economies. The
safety and health of the people we serve, our team members, their families, our stakeholders, broader communities and the
reliability of our health care systems consume our resources and our focus.
Care of Our Team Members
 Within days, 90% of our nonclinical workforce was
temporarily transitioned to a work at home status
while maintaining all service levels.
 We increased compensation for our front-line
clinical workforce in high incidence communities.
Serving Customers, Members and Patients
 Provided $1.5 billion in direct customer and
consumer support through premium credits, cost-
sharing waivers and other efforts. Expect another
$1 billion in rebates to be paid in future periods.
 Accelerated nearly $2 billion of payments to care
providers to provide needed liquidity for the health
system.
 Waived all cost sharing for COVID-19 diagnosis
and treatment.
 Provided unlimited free telehealth services.
 Removed all COVID-19 prior authorizations.
 Provided early refills, extended authorizations and
increased home delivery options of medication to
ensure no shortages.
 Extended grace periods for employers and
individuals to pay premiums.
 Deployed triage tools, including a symptom
checker with next best action recommendations.
 Shifted more than 14,000 OptumCare physicians to
telehealth for patient visits that would have
otherwise been canceled.
 Deployed 700 Advance Practice Clinicians to
expand telehealth services.
 Introduced a special enrollment period to allow
commercial customers to add employees who
previously declined health benefit coverage.
 Hired by California, Indiana and Jacksonville,
Florida to expand COVID-19 testing, with an
emphasis on serving underserved communities.
 Increased the number of behavioral health
professionals using our proprietary online
behavioral health platform by 45% to more than
10,000.
 Developed a cash discount option for members who
have lost pharmacy benefit coverage.
 Facilitated infusion services to the home that were
traditionally administered in hospital or clinic
settings.
Serving Society
 Selected by HHS to assist in processing and
distributing $100 billion CARES Act funding to
care delivery providers.
 Joined forces with Microsoft to launch
ProtectWell,™
an innovative return-to-workplace
protocol that enables employers to bring employees
back to the workplace.
 Developed and tested a new FDA approved self-
administered COVID-19 swab protocol and led a
study resulting in FDA approval for the use of
alternative swab materials, providing more options
for sample collection.
 Published a study with Yale School of Medicine
that showed the use of ACE inhibitors was
associated with an almost 40% lower risk of
COVID-19 hospitalization for Medicare Advantage
patients.
 Conducting a first of its kind 10,000-person virtual
clinical trial with Yale Medical School to examine
the potential role of ACE inhibitors in preventing
severe consequences of COVID-19.
 Partnering with the Morehouse School of Medicine
to study the effect of sickle cell trait, which is
prevalent in 8-10% of Black Americans, on
COVID-19.
 Partnered with Boston Scientific, Medtronic and the
University of Minnesota to develop and deploy
3,000 “light ventilators” to address critical
shortages.
 Donated $5 million to accelerate and expand Mayo
Clinic’s study of convalescent plasma treatments.
 Opened free access to our mental health mobile app
and 24/7 emotional support phone lines.
 Provided more than $100 million in support to date
to those affected by COVID-19, including
community relief efforts, health workforce safety,
seniors, and individuals experiencing homelessness
and food insecurity.
 Scaled a mobile and local testing program to
address health disparities and meet the unique
needs of disadvantaged communities in Los
Angeles, Philadelphia and Orleans Parish.
 Announced that we will not request, nor do we
intend to retain, any government assistance.

-- 5 of 14 --

Page 6 of 7
About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a diversified health care company dedicated to helping people live healthier lives
and helping make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products
and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits
services; and Optum, which provides information and technology-enabled health services. For more information, visit
UnitedHealth Group at www.unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter.
Earnings Conference Call
As previously announced, UnitedHealth Group will discuss the company’s results, strategy and future outlook on a
conference call with investors at 8:45 a.m. Eastern Time today. UnitedHealth Group will host a live webcast of this
conference call from the Investor Relations page of the company’s website (www.unitedhealthgroup.com). Following
the call, a webcast replay will be available on the same site through July 29, 2020. The conference call replay can also
be accessed by dialing 1-800-688-7339. This earnings release and the Form 8-K dated July 15, 2020, can also be
accessed from the Investor Relations page of the company’s website.
Non-GAAP Financial Information
This news release presents non-GAAP financial information provided as a complement to the results provided in
accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation
of the non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the
accompanying tables found at the end of this release.
Forward-Looking Statements
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking”
statements which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words
“believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar
expressions identify forward-looking statements. These statements may contain information about financial prospects,
economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that
management expects, depending on the outcome of certain factors including: risks associated with public health crises,
large-scale medical emergencies and pandemics, such as the COVID-19 pandemic; our ability to effectively estimate,
price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or
application; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve
improvement in quality scores impacting revenue; reductions in revenue or delays to cash flows received under
government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data
validation audits; failure to maintain effective and efficient information systems or if our technology products do not
operate as intended; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations;
risks and uncertainties associated with the pharmacy benefits management industry; competitive pressures; changes in or
challenges to our public sector contract awards; our ability to contract on competitive terms with physicians, hospitals
and other service providers; failure to achieve targeted operating cost productivity improvements; increases in costs and
other liabilities associated with litigation, government investigations, audits or reviews; failure to manage successfully

-- 6 of 14 --

Page 7 of 7
our strategic alliances or complete or receive anticipated benefits of strategic transactions; fluctuations in foreign
currency exchange rates; downgrades in our credit ratings; our investment portfolio performance; impairment of our
goodwill and intangible assets; and our ability to obtain sufficient funds from our regulated subsidiaries or from external
financings to fund our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly
dividend payment cycle, or continue repurchasing shares of our common stock. This above list is not exhaustive. We
discuss these matters, and certain risks that may affect our business operations, financial condition and results of
operations more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature,
forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and
assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or
implied in this document or any of our prior communications. You should not place undue reliance on forward-looking
statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking
statements, except as required by law.
# # #
Investors: Brett Manderfeld Media: Matt Stearns
Senior Vice President Senior Vice President
952-936-7216 202-276-0085

-- 7 of 14 --

UNITEDHEALTH GROUP
Earnings Release Schedules and Supplementary Information
Quarter Ended June 30, 2020
• Condensed Consolidated Statements of Operations
• Condensed Consolidated Balance Sheets
• Condensed Consolidated Statements of Cash Flows
• Supplemental Financial Information - Businesses
• Supplemental Financial Information - Business Metrics
• Reconciliation of Non-GAAP Financial Measure

-- 8 of 14 --

UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share data)
(unaudited)
Three Months Ended
June 30, Six Months Ended
June 30,
2020 2019 2020 2019
Revenues
Premiums................................................................................................................................................ $49,394 $47,164 $100,034 $94,677
Products.................................................................................................................................................. 8,247 8,353 16,678 16,425
Services.................................................................................................................................................. 4,156 4,496 9,141 8,814
Investment and other income.................................................................................................................. 341 582 706 987
Total revenues.................................................................................................................................... 62,138 60,595 126,559 120,903
Operating costs
Medical costs.......................................................................................................................................... 34,678 39,184 75,678 78,123
Operating costs....................................................................................................................................... 10,001 8,415 20,016 16,932
Cost of products sold.............................................................................................................................. 7,501 7,598 15,188 14,979
Depreciation and amortization................................................................................................................ 717 654 1,440 1,293
Total operating costs.......................................................................................................................... 52,897 55,851 112,322 111,327
Earnings from operations.................................................................................................................... 9,241 4,744 14,237 9,576
Interest expense..................................................................................................................................... (430) (418) (867) (818)
Earnings before income taxes............................................................................................................. 8,811 4,326 13,370 8,758
Provision for income taxes...................................................................................................................... (2,115) (941) (3,209) (1,816)
Net earnings ......................................................................................................................................... 6,696 3,385 10,161 6,942
Earnings attributable to noncontrolling interests..................................................................................... (59) (92) (142) (182)
Net earnings attributable to UnitedHealth Group common shareholders...................................... $6,637 $3,293 $10,019 $6,760
Diluted earnings per share attributable to UnitedHealth Group common shareholders .............. $6.91 $3.42 $10.43 $6.97
Adjusted earnings per share attributable to UnitedHealth Group common shareholders (a)...... $7.12 $3.60 $10.84 $7.33
Diluted weighted-average common shares outstanding......................................................................... 960 964 961 970
(a) See page 6 for a reconciliation of the non-GAAP measure
1

-- 9 of 14 --

UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions)
(unaudited)
June 30,
2020 December 31,
2019
Assets
Cash and short-term investments.................................................................................................................... $25,593 $14,245
Accounts receivable, net................................................................................................................................. 12,546 11,822
Other current assets........................................................................................................................................ 20,779 16,567
Total current assets................................................................................................................................. 58,918 42,634
Long-term investments.................................................................................................................................... 36,778 37,209
Other long-term assets.................................................................................................................................... 96,787 94,046
Total assets................................................................................................................................................ $192,483 $173,889
Liabilities, redeemable noncontrolling interests and equity
Medical costs payable..................................................................................................................................... $19,200 $21,690
Short-term borrowings and current maturities of long-term debt..................................................................... 6,156 3,870
Other current liabilities..................................................................................................................................... 44,527 36,222
Total current liabilities............................................................................................................................. 69,883 61,782
Long-term debt, less current maturities........................................................................................................... 39,901 36,808
Other long-term liabilities................................................................................................................................. 14,342 13,137
Redeemable noncontrolling interests.............................................................................................................. 1,842 1,726
Equity............................................................................................................................................................... 66,515 60,436
Total liabilities, redeemable noncontrolling interests and equity................................................................ $192,483 $173,889
2

-- 10 of 14 --

UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(unaudited)
Six Months Ended
June 30,
2020 2019
Operating Activities
Net earnings..................................................................................................................................................................... $10,161 $6,942
Noncash items:
Depreciation and amortization....................................................................................................................................... 1,440 1,293
Deferred income taxes and other.................................................................................................................................. 238 68
Share-based compensation.......................................................................................................................................... 388 398
Net changes in operating assets and liabilities................................................................................................................. 719 407
Cash flows from operating activities........................................................................................................................... 12,946 9,108
Investing Activities
Sales and maturities of investments, net of purchases (purchases, net of sales and maturities).................................... 573 (1,654)
Purchases of property, equipment and capitalized software............................................................................................ (920) (977)
Cash paid for acquisitions, net......................................................................................................................................... (3,952) (4,751)
Other, net.......................................................................................................................................................................... (186) 504
Cash flows used for investing activities...................................................................................................................... (4,485) (6,878)
Financing Activities
Common share repurchases............................................................................................................................................ (1,691) (4,501)
Dividends paid.................................................................................................................................................................. (2,212) (1,884)
Net change in short-term borrowings and long-term debt................................................................................................ 5,215 5,674
Other, net.......................................................................................................................................................................... 1,712 1,354
Cash flows from financing activities........................................................................................................................... 3,024 643
Effect of exchange rate changes on cash and cash equivalents...................................................................................... (143) 6
Increase in cash and cash equivalents............................................................................................................................. 11,342 2,879
Cash and cash equivalents, beginning of period.............................................................................................................. 10,985 10,866
Cash and cash equivalents, end of period....................................................................................................................... $22,327 $13,745
3

-- 11 of 14 --

UNITEDHEALTH GROUP
SUPPLEMENTAL FINANCIAL INFORMATION - BUSINESSES
(in millions, except percentages)
(unaudited)
Three Months Ended
June 30, Six Months Ended
June 30,
2020 2019 2020 2019
Revenues
UnitedHealthcare.................................................................................................................. $49,107 $48,594 $100,175 $97,490
Optum................................................................................................................................... 32,695 28,029 65,534 54,389
Eliminations.......................................................................................................................... (19,664) (16,028) (39,150) (30,976)
Total consolidated revenues........................................................................................... $62,138 $60,595 $126,559 $120,903
Earnings from Operations
UnitedHealthcare.................................................................................................................. $7,007 $2,642 $9,895 $5,596
Optum (a).............................................................................................................................. 2,234 2,102 4,342 3,980
Total consolidated earnings from operations.................................................................. $9,241 $4,744 $14,237 $9,576
Operating Margin
UnitedHealthcare.................................................................................................................. 14.3% 5.4% 9.9% 5.7%
Optum................................................................................................................................... 6.8% 7.5% 6.6% 7.3%
Consolidated operating margin...................................................................................... 14.9% 7.8% 11.2% 7.9%
Revenues
UnitedHealthcare Employer & Individual.............................................................................. $12,963 $14,032 $27,243 $28,116
UnitedHealthcare Medicare & Retirement............................................................................ 22,855 20,855 46,007 41,951
UnitedHealthcare Community & State.................................................................................. 11,523 11,186 22,976 22,368
UnitedHealthcare Global....................................................................................................... 1,766 2,521 3,949 5,055
OptumHealth......................................................................................................................... $9,139 $7,148 $18,331 $13,861
OptumInsight........................................................................................................................ 2,632 2,339 5,126 4,528
OptumRx............................................................................................................................... 21,371 18,923 42,928 36,740
Optum eliminations............................................................................................................... (447) (381) (851) (740)
(a) Earnings from operations for Optum for the three and six months ended June 30, 2020 included $841 and $1,553 for OptumHealth; $561 and $1,097 for
OptumInsight; and$832 and $1,692 for OptumRx, respectively. Earnings from operations for Optum for the three and six months ended June 30, 2019 included $688
and $1,314 for OptumHealth; $525 and $957 for OptumInsight; and $889 and $1,709 for OptumRx, respectively.
4

-- 12 of 14 --

UNITEDHEALTH GROUP
SUPPLEMENTAL FINANCIAL INFORMATION - BUSINESS METRICS
UNITEDHEALTHCARE CUSTOMER PROFILE
(in thousands)
People Served June 30, 2020 March 31, 2020 December 31, 2019 June 30, 2019
Commercial:
Risk-based............................................................................ 8,065 8,215 8,575 8,325
Fee-based............................................................................. 18,705 18,825 19,185 19,090
Total Commercial................................................................ 26,770 27,040 27,760 27,415
Medicare Advantage................................................................. 5,605 5,575 5,270 5,190
Medicaid.................................................................................... 6,210 5,880 5,900 6,360
Medicare Supplement (Standardized)....................................... 4,450 4,440 4,500 4,495
Total Public and Senior..................................................... 16,265 15,895 15,670 16,045
Total UnitedHealthcare - Domestic Medical.................... 43,035 42,935 43,430 43,460
Global........................................................................................ 5,365 5,605 5,720 6,070
Total UnitedHealthcare - Medical...................................... 48,400 48,540 49,150 49,530
Supplemental Data
Medicare Part D stand-alone............................................... 4,120 4,150 4,405 4,430
OPTUM PERFORMANCE METRICS
June 30, 2020 March 31, 2020 December 31, 2019 June 30, 2019
OptumHealth Consumers Served (in millions).......................... 97 96 96 95
OptumInsight Contract Backlog (in billions).............................. $19.4 $19.2 $19.3 $18.5
OptumRx Quarterly Adjusted Scripts (in millions)..................... 316 339 333 343
Note: UnitedHealth Group served 139 million unique individuals across all businesses at June 30, 2020.
5

-- 13 of 14 --

UNITEDHEALTH GROUP
RECONCILIATION OF NON-GAAP FINANCIAL MEASURE
(in millions, except per share data)
(unaudited)
ADJUSTED NET EARNINGS PER SHARE(a)
Three Months Ended
June 30, Six Months Ended
June 30,
Projected
Year Ended
December 31,
2020 2019 2020 2019 2020(b)
GAAP net earnings attributable to UnitedHealth Group common shareholders. $6,637 $3,293 $10,019 $6,760 $14,750 - $15,050
Intangible amortization........................................................................................ 267 240 532 467 ~1,025
Tax effect of intangible amortization.................................................................... (65) (60) (130) (116) ~(250)
Adjusted net earnings attributable to UnitedHealth Group common
shareholders............................................................................................ $6,839 $3,473 $10,421 $7,111 $15,525 - $15,825
GAAP diluted earnings per share........................................................................ $6.91 $3.42 $10.43 $6.97 $15.45 - $15.75
Intangible amortization per share........................................................................ 0.28 0.24 0.55 0.48 ~1.05
Tax effect per share of intangible amortization.................................................... (0.07) (0.06) (0.14) (0.12) ~(0.25)
Adjusted diluted earnings per share............................................................. $7.12 $3.60 $10.84 $7.33 $16.25 - $16.55
(a) Adjusted net earnings per share is a non-GAAP financial measure. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, or
superior to, financial measures prepared in accordance with GAAP.
Adjusted net earnings per share excludes from the relevant GAAP metric, as applicable, intangible amortization and other items, if any, that do not relate to the
Company's underlying business performance. Management believes that the use of adjusted net earnings per share provides investors and management useful
information about the earnings impact of acquisition-related intangible asset amortization. As amortization fluctuates based on the size and timing of the Company’s
acquisition activity, management believes this exclusion provides a more useful comparison of the Company's underlying business performance and trends from
period to period. While intangible assets contribute to the Company’s revenue generation, the intangible amortization is not directly related. Therefore, the related
revenues are included in adjusted earnings per share.
(b) Maintained from March 31, 2020.
6

-- 14 of 14 --